Aerovate Therapeutics, Inc. (AVTE) Misses Q3 EPS by 2c

Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q3 EPS of ($0.71), $0.02 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c